Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A multimarker real-time RT-PCR for MAGE-A gene expression allows sensitive detection and quantification of the minimal systemic tumor load in patients with localized cancer.
Mecklenburg I, Weckermann D, Zippelius A, Schoberth A, Petersen S, Prang N, Riethmüller G, Kufer P. Mecklenburg I, et al. Among authors: schoberth a. J Immunol Methods. 2007 Jun 30;323(2):180-93. doi: 10.1016/j.jim.2007.04.006. Epub 2007 May 15. J Immunol Methods. 2007. PMID: 17540401
Immunotherapy of malignant ascites with trifunctional antibodies.
Heiss MM, Ströhlein MA, Jäger M, Kimmig R, Burges A, Schoberth A, Jauch KW, Schildberg FW, Lindhofer H. Heiss MM, et al. Among authors: schoberth a. Int J Cancer. 2005 Nov 10;117(3):435-43. doi: 10.1002/ijc.21165. Int J Cancer. 2005. PMID: 15906359 Free article.
Immunomonitoring results of a phase II/III study of malignant ascites patients treated with the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3).
Jäger M, Schoberth A, Ruf P, Hess J, Hennig M, Schmalfeldt B, Wimberger P, Ströhlein M, Theissen B, Heiss MM, Lindhofer H. Jäger M, et al. Among authors: schoberth a. Cancer Res. 2012 Jan 1;72(1):24-32. doi: 10.1158/0008-5472.CAN-11-2235. Epub 2011 Nov 1. Cancer Res. 2012. PMID: 22044753 Clinical Trial.
First time intravesically administered trifunctional antibody catumaxomab in patients with recurrent non-muscle invasive bladder cancer indicates high tolerability and local immunological activity.
Ruf P, Bauer HW, Schoberth A, Kellermann C, Lindhofer H. Ruf P, et al. Among authors: schoberth a. Cancer Immunol Immunother. 2021 Sep;70(9):2727-2735. doi: 10.1007/s00262-021-02930-7. Epub 2021 Apr 10. Cancer Immunol Immunother. 2021. PMID: 33837852 Free PMC article.